Cellics Therapeutics
Cellics Therapeutics is a privately held, early-stage San Diego biotechnology company developing biomimetic nanomedicines to address unmet needs in inflammation and immunology, with no commercial products or disclosed revenue.
- Company typePrivate
- Founded2014
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cellics Therapeutics does
Cellics Therapeutics is a privately held, early-stage biotechnology company founded in 2014 and headquartered at 11588 Sorrento Valley Rd., Suite #20, San Diego, California. The company describes itself as developing biomimetic nanomedicines intended to address significant unmet medical needs in inflammation and immunology, positioning around a novel therapeutics platform rather than a disclosed named product or pipeline. Its corporate website is a 'Coming Soon' placeholder and no specific drug candidates, modalities, indications, clinical milestones, patents, certifications, or partnerships are disclosed in available materials.
The company has financed operations entirely through equity and non-dilutive capital, accumulating approximately $36.9M across five disclosed rounds between 2016 and 2022, including a CARB-X award in October 2020 indicating activity in antimicrobial-resistance therapeutics in addition to its inflammation/immunology positioning. Headcount is reported in the 11-50 range, consistent with a small R&D-stage team. There is no disclosed revenue, pricing model, or commercial channel because the company has not reached clinical or regulatory milestones that would enable product commercialization; distribution, pricing, and customer-facing infrastructure are therefore not yet applicable.
From a business-model standpoint, Cellics is a development-stage therapeutics company whose economics will depend on future licensing, partnership, or product-sale outcomes following clinical advancement and regulatory approval rather than current-period revenue. No management team, board composition, subsidiary structure, or strategic partnerships are disclosed beyond a founder attribution and a fragmented leadership roster. The overall signal is of a small, founder-led, capital-efficient nanomedicine platform that has secured multi-year funding but lacks public visibility into its current pipeline, clinical status, or forward funding trajectory.
Cellics Therapeutics firmographics
Firmographics- Name
- Cellics Therapeutics
- Legal name
- Cellics Therapeutics
- Website
- https://cellics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cellics Therapeutics is a privately held, early-stage San Diego biotechnology company developing biomimetic nanomedicines to address unmet needs in inflammation and immunology, with no commercial products or disclosed revenue.
- Ownership category
- akta.pro rank
Cellics Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Cellics Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cellics Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
Cellics Therapeutics product offering
Product offeringCore offering
Cellics Therapeutics is developing a novel therapeutics platform using biomimetic nanomedicines to address significant unmet needs in inflammation and immunology. The company operates as a single platform-based offering in the pre-commercial development stage, with its product pipeline marked as "Coming Soon" on the company website. No specific named products, modules, or commercial-stage offerings have been disclosed in available source materials.
Product overview
Cellics Therapeutics offers a novel therapeutics platform focused on addressing unmet needs in inflammation and immunology. The company appears to operate as a single platform-based offering rather than a multi-product portfolio, though no specific named products, modules, or sub-brand offerings are detailed in the available source materials.
Differentiator
Problem solved
Functional benefit
Products and services
- Biomimetic nanomedicines therapeutics platform (in development) A novel therapeutics platform based on biomimetic nanomedicines targeting unmet needs in inflammation and immunology. Currently in pre-commercial development with a "Coming Soon" status on the company website; no named commercial products, modules, or sub-brand offerings are disclosed.
Companies that use Cellics Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Cellics Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cellics Therapeutics partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Cellics Therapeutics competitors and assessment
Company assessmentEmerging players
- Intellia Therapeutics: Clinical-stage biotech developing in vivo gene editing therapies using lipid nanoparticle delivery for inflammatory and genetic diseases. Comparable as an early-stage, platform-based therapeutics company innovating in delivery technologies.
- Equillium: Clinical-stage biotechnology company developing immunomodulatory therapies for severe autoimmune and inflammatory disorders. Comparable as a focused inflammation/immunology therapeutics company in early-stage development.
- RAPT Therapeutics: Clinical-stage immunology company developing oral small molecules for inflammatory diseases. Comparable as a focused inflammation therapeutics peer in similar development stage.
- Landos Biopharma: Clinical-stage biopharmaceutical company developing novel oral therapeutics for autoimmune diseases. Comparable as an early-stage immunology therapeutics developer.
- Laronde (Eclipse Bioinnovations successor): Developed programmable RNA medicines via the Endless RNA (eRNA) platform and nanoparticle delivery. Comparable as an innovative delivery-platform therapeutics company in the inflammation/immunology adjacent space.
- Capstan Therapeutics: Develops cell-targeted lipid nanoparticle therapeutics, including in vivo CAR-T cell engineering approaches. Comparable as a delivery-platform company leveraging biomimetic and nanoparticle technologies for immunology.
Direct peers
- Selecta Biosciences: Develops immune tolerance technologies, including nanoparticle-based approaches to treat autoimmune and inflammatory diseases. Comparable as a nanoparticle-delivery therapeutics company targeting immunology indications.
- Arcturus Therapeutics: Focused on RNA-based therapeutics and lipid nanoparticle delivery technologies. Arcturus is comparable as a delivery-platform-centric therapeutics developer tackling inflammation and rare diseases with novel nanoparticle modalities.
- Rubius Therapeutics: Develops engineered red blood cell-based therapeutics, including products for immunology and inflammation. Rubius is the closest direct peer to Cellics given its use of cell-membrane-derived biomimetic approaches to address inflammatory and immune diseases.
Others
- CytoSorbents Corporation: Commercial-stage company using biomimetic blood-purification polymer technology to treat inflammatory conditions in critical care. Comparable as a biomimetic-medicine adjacent technology company addressing inflammation.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Cellics Therapeutics social profiles
Digital presenceCellics Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellics Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Cellics Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellics Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellics Therapeutics
What does Cellics Therapeutics do?
Cellics Therapeutics is developing a novel therapeutics platform using biomimetic nanomedicines to address significant unmet needs in inflammation and immunology. The company operates as a single platform-based offering in the pre-commercial development stage, with its product pipeline marked as "Coming Soon" on the company website. No specific named products, modules, or commercial-stage offerings have been disclosed in available source materials.
Is Cellics Therapeutics a public or private company?
Cellics Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cellics Therapeutics founded?
Cellics Therapeutics was founded in 2014. It employs 11 to 50 people.
Where is Cellics Therapeutics based?
Cellics Therapeutics is headquartered in San Diego, United States, in the North America region.
Who are Cellics Therapeutics's main competitors?
Emerging players on record are Intellia Therapeutics, Equillium, RAPT Therapeutics, Landos Biopharma, Laronde (Eclipse Bioinnovations successor) and Capstan Therapeutics. Direct peers are Selecta Biosciences, Arcturus Therapeutics and Rubius Therapeutics. CytoSorbents Corporation is listed as an others.
Does Cellics Therapeutics have an API?
No public API is recorded for Cellics Therapeutics.
What industry is Cellics Therapeutics in?
Cellics Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.